This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Renagel

Sanofi

Drug Names(s): Tasermity (EU)

Description: Renagel prevents phosphate absorption by binding to dietary phosphate in the gastrointestinal tract. Renagel is a polyamine - a polymer that is loaded with amines. The amines provide a large number of positive charges that binds to the negatively charged phosphate anions.

Deal Structure: Historical drug revenue includes Renagel and Renvela.

In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.

Partners: Chugai Pharmaceutical Co., Ltd.


Renagel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug